BURLINGTON, ON, Oct. 4, 2012 /PRNewswire/ - EKO International
Inc. (EKNL-Pinksheets) announces that NeuroVasc Clinical Inc.,(
NCI) is commencing an awareness campaign notifying health care
practitioners that clinics providing treatment for Diabetic
Peripheral Neuropathy will soon be available for their patients.
Diabetic neuropathies, affect over 50% of diabetics. If left
untreated, diabetic neuropathies trigger foot ulcers that may
require amputation, may cause disabling chronic pain and may
increase the risk of falling to the elderly. The annual cost of
diabetic neuropathies has been estimated at $14 billion in the
United States.
The treatment of Diabetic Peripheral Neuropathy is the main
intended use for the proprietary FREMS device now being distributed
in North America by NCI.
NCI also distributes the NC-Stat DPN check device which is a
point of care nerve conduction measurement tool essential in the
early detection of peripheral neuropathy. Patients who score poorly
on the nerve conduction test are prime candidates for FREMS
treatments and this is very valuable information for Physicians,
Pharmacists , Podiatrists and Certified Diabetic Educators .
EKO, NeuroVasc Medical Inc. and NCI will continue to support the
Canadian and American Diabetes Associations' call for the annual
testing of all diabetics for peripheral neuropathy and will work to
educate the community about the role FREMs can play in treating
neuropathy and in preventing leg ulcers and their devastating
complications.
Of interest is the following quote:
"Is the testing service now available to the general
public and where can it be found?
The product is relatively new to the market having been
introduced late last year. Through the end of June, we've placed
590 devices with physicians and health care professionals in
North America, including
WalMart-Canada pharmacies where the test is offered as a part of a
comprehensive foot examination at 100 of their stores.
Also, the large San-Antonio,
Texas based managed care organization, WellMed, has adopted
the technology and plans to test its patient population numbering
about 100,000. "-News Medical-
http://www.news-medical.net/news/20120806/Medical-devices-for-diabetic-peripheral-neuropathy-an-interview-with-Dr-Shai-Gozani-CEO-of-NeuroMetrix.aspx
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by EKO International ("The Company") are "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934. You
should not place undue reliance on forward-looking statements since
they involve known and unknown risks, uncertainties and other
factors, which are, in some cases, beyond the Company's control and
which could, and likely will, materially affect actual results,
levels of activity, performance or achievements. The Company
assumes no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons
actual results could differ materially from those anticipated in
these forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
SOURCE EKO INTERNATIONAL CORP.
